Uptitration of drugs for chronic systolic heart failure stops farther away from the recommended dosage for drugs with higher versus lower recommended dosages.
The FDA has approved Entresto for the treatment of symptomatic heart failure in pediatric patients.
The FDA has approved a new indication for Invokana to reduce the risk of end-stage renal disease, doubling of serum creatinine, CV death, and more in T2D.
Dapagliflozin use was linked to an in increase in the proportion of patients experiencing clinically meaningful improvements in HF-related health status in HFrEF.
Investigators analyzed the relationship between ICD use and all-cause mortality in a modern cohort with heart failure with reduced ejection fraction and evaluated relevant subgroups.
Sacubitril–valsartan was not linked to a lower rate of death from cardiovascular causes among patients with heart failure with preserved ejection fraction.
The American College of Cardiology has developed a new expert consensus decision pathway for risk assessment, management, and clinical trajectories of patients hospitalized with heart failure.
Investigators sought to determine the effect of serelaxin infusion on incidence of death from cardiovascular causes at 180 days in patients hospitalized for acute heart failure.
Researchers examined whether the difference in the circulating levels of each brain natriuretic peptide molecular form is related to the incidence of worsening renal function in acute heart failure.
County-level poverty is strongly associated with heart failure and CHD mortality, and the correlation is stronger for heart failure mortality.